Immunovia ABIMMVF -61.59%43 Days Payable is 3,692.58 as of Mar. 2026, which is 1735% above its 10-year median of 201.27. GuruFocus rates IMMVF with a GF Score™ of 43/100 and a GF Value™ of $0.01. The stock has 4 warning signs investors should review. Among 190 Medical Diagnostics & Research companies, Immunovia AB ranks better than 97.89% on this metric.
The historical rank and industry rank for Immunovia AB's Days Payable or its related term are showing as below:
IMMVF'
s Days Payable Range Over the Past 10 Years
Min: 111.32 Med: 201.27 Max: 8747.92
Current: 4264.22
During the past 13 years, Immunovia AB's highest Days Payable was 8747.92. The lowest was 111.32. And the median was 201.27.
IMMVF's Days Payable is ranked better than 97.89% of 190
companies
in the Medical Diagnostics & Research industry
Industry Median: 67.275
vs IMMVF: 4264.22
Immunovia AB's Days Payable
increased
from Mar. 2025 (0.00) to Mar. 2026 (3,692.58).
It may suggest that Immunovia ABdelayed paying its suppliers.
Immunovia AB Days Payable Related Terms
Immunovia AB Days Payable Historical Data
* Premium members only.
The historical data trend for Immunovia AB's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Immunovia AB's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Immunovia AB Days Payable vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Immunovia AB's Days Payable distribution charts can be found below:
* The bar in red indicates where Immunovia AB's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Immunovia AB's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Immunovia AB (IMMVF) has a Days Payable of 3,692.58 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Immunovia AB and its competitors. This is 1735% above median its historical median of 201.27. Over the past decade, Immunovia AB's Days Payable has ranged from 111.32 to 8,747.92. According to the industry distribution chart, Immunovia AB ranks #4 out of 190 companies in the Medical Diagnostics & Research industry, placing it in the top 2.1%.
Is Immunovia AB's Days Payable too high?
Immunovia AB's current Days Payable of 3,692.58 is 1735% above median its 10-year median of 201.27. Over the past 10 years, this metric has ranged from a low of 111.32 to a high of 8,747.92. The Medical Diagnostics & Research industry median Days Payable is 67.28. Immunovia AB's value of 3,692.58 is 5388.8% above this industry median. Based on the distribution chart, Immunovia AB ranks #4 out of 190 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Immunovia AB has a GF Score™ of 43/100, reflecting its overall financial health beyond just this single metric.
How does Immunovia AB's Days Payable compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Immunovia AB ranks #4 out of 190 companies for Days Payable. This places Immunovia AB in the top 2% of its industry — outperforming the majority of peers. The industry median Days Payable is 67.28. Immunovia AB's value of 3,692.58 is 5388.8% above this benchmark. Historically, Immunovia AB's own Days Payable has ranged from 111.32 to 8,747.92 over the past decade. While the company's 10-year median is 201.27 vs. the industry median of 67.28, Immunovia AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Diagnostics & Research company?
The median Days Payable among Medical Diagnostics & Research companies is 67.28, based on 190 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Immunovia AB's current Days Payable of 3,692.58 is 5388.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Immunovia AB and its competitors. For the Medical Diagnostics & Research industry, the median Days Payable is 67.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Immunovia AB's current Days Payable is 3,692.58, which is 1735% above median its own 10-year median of 201.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Immunovia AB stock overvalued right now?
Immunovia AB (IMMVF) has a current Days Payable of 3,692.58. The stock's GF Value™ is $0.01, compared to a current price of $0.02 — trading 100% above its estimated fair value. The current Days Payable is 3,692.58, which is 1735% above median its 10-year median of 201.27 and 5388.8% above the Medical Diagnostics & Research industry median of 67.28. Immunovia AB's overall GF Score™ is 43/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Immunovia AB (IMMVF), the current Days Payable is 3,692.58 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Immunovia AB (IMMVF) Overvalued in 2026?
Based on GuruFocus' analysis, Immunovia AB stock appears to be overvalued.
The current stock price of $0.02 is trading 100% above its estimated GF Value™ of $0.01.
Key valuation signals for IMMVF:
Days Payable: 3,692.58 (1735% above median its 10-year median of 201.27)
GF Value™: $0.01 vs. price of $0.02 (100% above fair value)
Industry Position: 5388.8% above the Medical Diagnostics & Research median (#4 of 190)
No single metric tells the full story. See the IMMVF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Immunovia AB is a diagnostic company. The company develops and commercializes diagnostic tools to detect proteins and autoimmune diseases. The company is developing its next-generation blood test to detect pancreatic cancer in high-risk individuals. IMMray platform is dedicated to the early detection of pancreatic cancer. Its technology platform IMMray (TM), is based on antibody microarray analysis.
43GF Score
Get the complete analysis for IMMVF
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IMMVF has been successfully added to your 
